The gospel of epilepsy patients, Eisai Perampanel is about to expand the indication population in China

A few days ago, the status of the 5.

Epilepsy, commonly known as "claw wind" or "sheep epilepsy", is a chronic disease that causes sudden abnormal discharge of brain neurons, leading to transient brain dysfunction

Perampanel (Fycompa) is a pioneering anti-epileptic drug (AEDs) developed internally by Eisai.

In July 2012, Fycompa was the first to be approved in Europe as an adjuvant therapy for partial-onset epilepsy (with or without secondary generalized seizures) and primary generalized tonic spasticity in patients with epilepsy of 12 years and older For the treatment of epilepsy, the indication was approved in the United States in October 2012

Up to now, Fycompa has been approved for marketing in more than 70 countries and regions around the world, and has been widely used to treat more than 300,000 patients worldwide

In addition, Eisai is also conducting a phase III clinical study (Study 338) worldwide, which aims to use Fycompa for the treatment of seizures associated with Lennox-Gastaut syndrome

In China, perampanel was approved by the NMPA in September 2019 for the adjuvant treatment of partial-onset epilepsy (with or without secondary generalized epilepsy) in patients with epilepsy aged 12 years and older.

It is worth mentioning that perampanel is included in the "Second Batch of Encouraging Generic Drugs List" issued by the National Health Commission and other six departments in 2021.